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Summary The purpose of this study was to define a correlation between telomerase actvity and human papillomavirus (HPV) in normal
control tissue and in benign, premalignant and malignant cervical lesions. Telomerase actvity was detectable in 33 out of 34 cases of
squamous-cell carcinoma, five out of six cases of microinvasive carcinoma, 8 out of 20 cases and two out of six cases of high- and low-grade
squamous intraepithelial lesions (SILs) respectively. The higher frequency of positive telomerase in invasive carcinoma compared with SILs
was observed in both HPV-associated and non-associated groups. Whereas 92.6% of HPV-positive and 100% of HPV-negative invasive
lesions expressed telomerase, only 50% of HPV-positive and 25% of HPV-negative SILs did. Interestingly, telomerase activity was also
detectable in 13 out of 28 cases of benign lesions regardless of the presence of HPV. In conclusion, there may be two roles of telomerase in
the cervix. The first one would present in benign lesions; the second is associated with cancer development and activated dunng the late
stage of multistep carcinogenesis in both HPV-positive and -negative groups.
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Cervical neoplasm is one of the most common malignancies in
woman encountered worldvide. especially in developing coun-
tries (Whelan et al. 1990). E-idence from molecular studies
stronclr- confirmed the pathogenic plausibility of human papillo-
mavirus (HPV) infection in more than 75%7 of cervical neoplasms
(Bosch et al. 1995: Schiffman et al. 1993). Other -iruses. smokine.
immunodeficiencN- and other factors related to acquirinr venereal
disease mav be iri-olved. Interestingly. HPV-nerative preneo-
plastic lesions were shown to be due to different risk factors.
These lines of evidence suggrest that HPV-positix-e and -negatixe
cerx-ical carcinogenesis are two separate entities (Burger et al.
1996).
The HPVs can be broadly classified into low- and inter-
mediate/high-risk groups based on their association w-ith low-- and
high-grade cervical lesions (Bosch et al. 1995: Schiffman et al.
1993). The role that high-risk HPV plays in cervical carcinogen-
esis could be due to effects ofHPV protein expression that interact
with and change cellular phenotypes. One of the most crucial
changes is actix-ation of telomerase leading to immortalization
(DiPaolo et al. 1993: Klingelhutz et al. 1996: Steenbergen et al.
1996). The purpose of this study is to determine if HPV infection
is associated w-ith telomerase activity in x-iN-o and if there is a
difference betsxeen HPV-positix-e and- negative cerx-ical tissues
regarding their respective telomerase actixitV.
A sensitixe polxmerase chain reaction (PCR)-based assay to
detect telomerase activity. the TRAP assay. A-as recently used to
detect the malignant phenotype in x-arious tissues as telomerase
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was thouaht to be activated specifically in malignant but not in
most normal tissues (Kim et al. 1994). Furthermore. studies of
telomerase activity in premalignant lesions help define howi telom-
erase is associated with multistep carcinogenesis and. if
detectable. the telomerase assay can be applied for early detection
ofcancer (Mutirangura et al. 1996: Shav and Gardar 1997).
Specific histological classifications differentiate cerxical
premalignant and malignant lesions as loby-gfrade and high-grade
squamous intraepithelial lesions (SILs) and invasive carcinoma
(Lundberg. 1989). Recent studies demonstrated a higher frequency
of telomerase actixitv in cervical cancer (88-100%c) than SILs
(25-59%7) (Anderson et al. 1997: Kyo et al. 1997: Pao et al. 1997:
Zheng et al. 1997). In addition. this higherfrequency oftelomerase
expression w-as discovered in both HPV-positive and -neaative
cervical cancers (Anderson et al. 1997). In this study. vwe corre-
lated the presence of telomerase activity with the HPV status in
normal controls. benign lesions. SILs and squamous-cell carci-
nomas ofthe cervix. Our results suggest that telomerase actix itv is
detectable in epithelial tissue not only in premalignant and malig-
nant but in benign cervical lesions. In addition. the presence of
hiah-risk HPV was not associated w-ith telomerase expression in
benign cernical lesions. Finally. a significantly elex ated frequency
of telomerase activitxvwas discovered in microinvxasive carcinoma
and cancer compared with SILs obtained from both HPV-positixe
and -negative groups. Thus. there may be two roles for telomerase
in the cervix. The first one would be physiological and could be
present in benign lesions regardless of their HPV status. The
second one is associated with cancer development and activated
during the late staae ofmultistep carcinogenesis in both HPV-posi-
tive and -nerative groups.
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Figure 1 Teomerase activity in cervical tissues, (+ and -, with and without RNAase pretreatnent respectivety). ITAS, intemal teomnerase assay standard.
Extracts of Epstein-Barr virus transformed human lymphocyte cell lines were used as positive control. Serial diluton of 103, 102 and ten cells represented levels
of acvty of the enzyme. CHAPS Wysis buffer (B) was used as negative control. Samples C32, cervical cervicitis, C37, high-grade SILs, C57, MIC and C124,
cervical cancer exhibited positive teloerase actity. Sample C82, normal cervix exhibited negative telomerase actvity
Table 1 Telomerase acy. HPV type and cervical lesions
Normal Benign Low-grade High-grade MIC Squamous
cervical SLs SILs cell
kksions
Tebxmeraseactivity + - + - + - + - + - + -
HPV + 1 3 1 4 1 0 6 7 4 1 21 1
High nsk 0 1 1 3 0 0 4 5 4 1 17 0
Low risk 0 0 0 0 1 0 0 0 0 0 0 0
Unknown 1 2 0 1 0 0 2 2 0 0 3 1
HPV- 0 5 12 11 1 4 2 5 1 0 12 0
Total 1 8 13 15 2 4 8 12 5 1 33 1
Allcases 9 28 6 20 6 34
SILs. squamous intraepithelial lesions; MIC microinvasive carcinoma; HPV, human papillomavirus: +, positive; -. negative; high nsk. HPV type 16, 18 and 33:
low risk. HPV type 11: unknown, positive for generic HPV DNA probe but not HPV type 6, 11, 16. 18. 31 and 33 specific probes, Benign cervical lesions include
cervicits. squamous metaplasia, polyp. atypical gland and exophytic condyoma.
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MATERIALS AND METHODS
Cervical specimens
Samples uxere obtained by punch biopsy of lesions under direct
x-isualization or under colposcopic examination. Specimens were
divided into tx-o parts. The first part was submitted to routine
histological examination. For the second part. a sample uas
further dissected and divided into two equal quantities. One part
xas placed in collagenase solution (collagenase 200 u ml-': RPMI
buffer) for 24 hs. After enzymatic separation. epithelial cells and
adjacent connective tissue were harvested separately. snap frozen
and stored at -80^C until further use (Freshney 1987). The other
part w as immediately stored at -80-C for subsequent TRAP
analy-sis. The small sample w-as kept at -80^C for subsequent
TRAP analysis only.
Histological examination of all samples was performed by one
pathologist (SN). The histological diagnoses distinguished
betwxeen normal epithelium. benign lesions (such as cerxicitis.
polyp. exophytic condvloma. atypical glands and squamous meta-
plasia). low-grade SILs. high-grade SILs. microinxasive and inva-
six e carcinoma. In cases of invasihe carcinoma. only those
classified as squamous-cell lesions were used for further analysis.
TRAP assay
TRAP x-as performed as described previously (Kim et al. 1994:
W'riaht et al. 1995). Briefly. each frozen tissue x-as first wxashed in
500 jl of ice-cold phosphate-buffered saline (PBS). then homoge-
nized in 20-200 jl of ice-cold CHAPS lyvsis buffer according to
the size of sample with a manual homogenizer. The collagenase-
treated specimens wxere x-ashed x-ith ice-cold PBS and treated wxith
lvsis buffer A-ithout homogenization. After 30 mmn incubation on
ice. the lysate x-as centrifuged at 14 000 g for 30 min at 4 C. The
supernatant x-as aliquoted. flash frozen in liquid nitrogen and
stored at -800C until further analvsis. The pellets were kept for
subsequent HPV analx-sis.
Epstein-Barr virus-transformed human lymphocvtes American
Type Culture Collection Cell Line. B958) wxere used as positixe
controls. The PCR-based assay xxas carried out in a 50-gl reaction
mixture containing 2jig of the extracted protein. 20 mixi Tris-HCl
(pH 8.3). 1.5 m-Mi magnesium chlonrde. 63 m.Mm potassium chloride.
0.005%Oc Tween-20. 1 mnm EGTA. 50 Im dGTP. dATP and dTTP. 5
jim dCTP. 0.1 jIc of TS. 1 jgc of T4a32 protein. 4 jl of [a-
'PIdCTP (IOpCi jl-1. 3000 Ci mmol- ). 2 units of Taq pol-
merase. 5 x 10-1> of internal telomerase assay standard (ITAS) in
a 0.5-ml tube. containin, 0.1 pg of 5'-[CCCTTA]CCCTAA-3'
CX) sealed at the bottom by a A ax barrier.
After 10 min incubation at 23-C to alloxx telomerase-mediated
extension of the 5'-AATCCGTCGAGCAGAGTT-3' (TS) primer.
the reaction mixture wxas then subjected to 30 PCR cycles at 94 C
for 1 min. 5O3C for 1 min and 72 C for 1 mmn. Aliquots (5 of
the PCR products wxere analysed on an 8%7c non-denaturing, poly-
acrxlamide gel. The gel xxas subsequently exposed to a Kodak
XAR-5 X-rav film at -70^C xxith an intensifxinc screen.
Duplicated assay s xxere performed on all samples xxith RNAase
pretreatment at a final concentration of0.05 mg ml-' for 10 mmn at
room temperature. The positixe results xxere compared x-ith the
telomerase actixvitv of ten. 100 and 1000 cells of B958.
The samples exhibiting negative ITAS were subjected to tx-o-
step TRAP (1W Shay personal communication). The first part
consisted of TS primer extension w-ith a 50-gl reaction mixture
containing, 2jg of the extracted protein. 20 mmi Tris-HCI. 1.5 mm
MgC1,. 63 mnI\ KCI. 0.005',7c Tleen-20. 1 mm EGTA. 50 gm of
each dNTP. 0.1 g,g of TS. 1 i,g of T4g32 protein and DEPC H,O.
The reaction tube was incubated in the thermocxcler at 23-C for
15 min. The product was then subjected to standard phenol-chlo-
roform DNA extraction and ethanol precipitation. The precipitate
was dissoIxed and amplified in the second part. The second part
reaction mixture was the same as in the non-modified TRAP wxith
the incubation at 23 C for 15 min omitted. The amplification cycle
was the same as the original protocol.
Positive assays were reconfirmed with and without RNAase
pretreatment with newlxl described primers (Kim et al. 1997). The
PCR-based assax wxas carried out in a 50-gl reaction mixture
containing 2go ofthe extracted protein. 20 mxt Tris-HCI (pH 8.3).
1.5 mMN MgCI,. 63 nm-i KCI. 0.005%7 Tween-20. 1 n_\t EGTA.
50 }1X1 dGTP. dATP and dTTP. 5 gm dCTP. 0.1 jIc of TS. 1 jci of
T4g32 protein. 4 g1 of [a-"'P] dCTP (10 jCi gl-'. 3000 Ci
mmol- ). 2 units of Taq pol-merase and DEPC H,O in a 0.5-ml
tube. containing 0.1 jge of 5'-GCGCGG[CTT-ACC],CTAACC-3
(ACX) sealed at the bottom bv a wax barrier.
After 10 min incubation at 23-C to allow telomerase-mediated
extension of the TS primer. the reaction mixture was subjected to
30 PCR cNcles at 94C for 1 min. 50fC for 1 mmn and 72C for
1 mmn. Aliquots (5 jl) of the PCR products were anal-sed on an
8%7c non-denaturin, polvacrylamide gel. The gel wxas subsequently
exposed to a phosphor screen and the bands were visualized on a
Phosphorimager using Image Quant software (Molecular
Dxnamics. Sunnyvale. CA. USA).
HPV PCR
Pellets derixed from the prexvious extraction with CHAPS l-sis
buffer were subjected to standard DNA extraction (NManiatis et al.
1989). The DNA xxas used for subsequent HPV PCR. Control HPV
DNA used in the amplification was obtained from Hela cell lines.
LI and E6 amplification were performed as previously described
(Resnick et al. 1990: Bauer et al. 1991) with 1 g1 of each specimen
in a 50-pl reaction mixture. Each L1 amplification reaction
contained 25 pmol each of the LI degenerate primers MY11 and
MY09 and 2.5 pmol each of$-globin primers GH-0 and PCO4. The
E6 reactions contained 5 pmol of WD72. AD66 and AWD154.
20 pmol of WD67 and WD76. Both reactions wxere performed in a
buffer containing 50 m.x\ KCI. 10 mn\t Tris (pH 8.3). 4 mn-\iMgCl,.
200 L\I of each dNTP and 1.25 units of Taq pol-merase and
subjected to 40 amplification cdcles. Each cycle wxas performed at
95^C for 1 min. at 55-C for 1 mmn and at 72:C for 2 min. An addi-
tional 5-min final elonoation cvcle at 72'C wxas included. The PCR
reactions wxere then separated by 2% agarosegel electrophoresis and
visualized under UV illumination after ethidium bromide stainin,.
Dot hybridization of PCR products
Ll and E6 type-specific probes and consensus Ll probes xxere
used for HPV typing. Positix e controls of HPV type 6. 11. 16. 18.
31 and 33 from each PCR amplification were included. Products
obtained from each PCR reaction wxere heated to 95-C and there-
after 1 volume of 20 x SSC was added. Aliquots of 2 il were
applied to a H\ybond-N- nylon membrane (Amersham. Life
Science) prewetted in denaturing solution (1.5 \i NaCl. 0.5 xi
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Figure 2 Telomerase activity in benign cervical lesions using the new set of prinmers (+ and -. with and without RNAase treatment respectively). Extracts of
Epstein-Barr virus transformed human tymphocyte cell lines were used as posibtve control. Serial diluton of 103, 102 and ten cells represented levels of actvity
of the enzyme. Samples C58. C109. C157 and C187 were cervicitis. atypical gland. squamous metaplasia and polyp respectively
Table 2 Telorerase expression level, HPV status and cervical lesions
Benign cervical lesions SlLs INV CA
Tekbmerase activity HPV+ HPV- HPV+ HPV- HPV+ HPV-
Positive 1 12 7 3 25 13
<100 1 10 2 4 1
100-1.000 1 4 3 5 3
>1000 1 1 16 9
Negative 4 11 7 9 2 0
Total 28 26 40
HPV+. positive for human papillomavirus DNA; HPV-. negative for human papilomavirus DNA; INV CA. invasive carcinoma.
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NaOH). The membranes were transferred to a filter paper soaked
in neutralizing solution (1.5 M NaCl. 0.5 M Tris-HCI pH7.2.
0.001 M EDTA) for 1 min. The membranes were air dried at room
temperature. soaked in 0.4 M NaOH for 20 min for fixation and
washed with 5 x SSC. Prehybridization at 65°C for 1 h was carried
out using 6 x SSC. 5 x Denhardt's solution. 0.5% SDS. 100 jig of
single-stranded sheared salmon sperm DNA per miuilitre.
Replicate membranes were separately hybridized with denatured
'P-labelled. type-specific probes in prehybridizing solution for 1 h
at 55°C. Probes WD170 required hybridization at 45°C. Filters
were rinsed briefly in 2 x SSC and 0.1% SDS at room temperature
and then twice for 10 min at 45°C (WD170), 50-52°C (WD132.
RRI and RR2). 55-56°C (WD103, WD165 and WD166).
56-57°C (consensus LI, MY12/13, WD126. WD128, MY16 and
WD133/134) or 58-590C (MY14 and WD74). The membranes
were subjected to autoradiography using a Kodak XAR-5 film.
Results of LI and E6 dot blots were scored independently.
Duplicate filters were prepared for all specimens.
Data and statistical analysis
Data in each part histology. TRAP assay. HPV PCR and typing.
were collected in a double-blind fashion until further analysis. The
chi-square test was used tocomparethe resultsobtained fromtelom-
erase analysis with those ofHPV and pathological parameters.
RESULTS
Telomerase acivity in cervical lsions
In the present study, we analysed nine samples ofnormal controls.
28 of benign cervical lesions. six of low-grade SILs. 20 of high-
grade SILs. six ofmicroinvasive carcinoma (MIC) and 34 ofsqua-
mous-cell carcinoma of the cervix. The benign cervical lesions
included 19 cases of cervical cervicitis, four cases of squamous
metaplasia. two cases of atypical gland, two cases of polyps and
one case ofexophytic condyloma. Telomerase was found activated
in five cases ofMIC and 33 cases of squamous-cell carcinoma. A
decreased incidence ofexpression was identified in SILs, two out
of six cases oflow-grade SILs and 8 out of20 cases ofhigh-grade
SILs (Figure 1 and Table 1). Interestingly, 13 out of 28 cases of
benign cervical lesions, eight cases ofcervicitis, two cases ofatyp-
ical glands. two cases of squamous metaplasia and one case of
polyps, and one out ofnine cases ofnormal controls were positive
for telomerase activity. (Figure 2 and Table 1)
Because the cervical lesions showed variations regarding the
intensity of the TRAP signals, we compared the intensity of the
ladder signals with serial dilutions of the cell line B958, 100 and
1000 cells respectively. A gradual increment of TRAP intensity
was observed that varied in direct proportion to the number ofthe
immortalized cells tested. We then semiquantitatively compared
the density of each positive TRAP result with the serially diluted
B958 cell line (Table 2). The dosage of telomerase activity was
then recorded as <100, 100-1000. or >1000, indicating whether
the intensity ofthose bands was less than 100, or between 100 and
1000 or more than 1000 B958 cells respectively. The variation in
expression oftelomerase has been detected in all types ofcervical
lesions. Nevertheless, in general the invasive cancers expressed
the highest telomerase activity and the benign lesions and normal
cervical tissues expressed the lowest. This comparison was valid
in both HPV-positive and -negative groups.
In order to identify whether telomerase expression originated
from epithelium or activated lymphocytes in connective tissue.
collagenase treatment was applied to some SILs and benign
lesions. In the case of most lesions. a higher level of telomerase
activity was detected in epithelial tissues. In addition. there were
four cases of SILs and one case of cervicitis where we could
ascribe the telomerase activity exclusively to the epithelium.
Hence. detectable telomerase activity should be located within the
epithelial layer ofthe cervix (Figure 3).
Telomerase activity, HPV status and cervical lesions
This study identified HPV in 24%. 54% and 68% of benign
cervical lesions. SILs, and invasive carcinoma respectively.
Among these HPV-positive samples. intermediate/high-risk HPV.
type 16. 18 or 33, was detected in 36 out of 48 cases. Low-risk
HPV was identified only in one case of low-grade SILs. The
remaining samples were not positive for type 6. 11. 16, 18. 31 and
33 specific probes (Table 1 and Figure 4).
Although HPV was detectable in the cervices ofall grouptested.
a different frequency of positive TRAP assay was observed when
comparing the groups (Table 2). Whereas 93% of HPV-positive
cancers showed telomerase expression. only 50% of SILs
expressed the enzyme (P<0.005; cancer vs SILs). Interestingly. a
significant distinction regarding telomerase activity was also
observed between SILs and cancer cases in the HPV-negative
group (P<0.OO1). This suggests that telomerase may be activated
during late multistep carcinogenesis in both groups.
As for benign cervical lesions. no significant correlation of
telomerase activity with the HPV status (p>0.5) became apparent.
Whereas 20% ofHPV-positive cases exhibitedtelomerase activity,
52% of the HPV-negative group were telomerase positive in the
TRAP assay. This may imply that HPV infection does not lead to
telomerase activation in benign cervical lesions (Table 2).
DISCUSSION
Telomerase is a ribonucleoprotein enzyme that synthesizes telom-
eres, the specialized structures containing unique simple repetitive
sequences (TTAGGG in vertebrates) at the end of chromosomes
(Blackburn 1991: Feng et al, 1995). The enzyme activity provides
the means to compensate for the end replication problem and thus
expression oftelomerase might be acrucial factor allowing cells to
proliferate indefinitely (Counter et al. 1992). Once thought to be
cancer-cell specific, it is becoming apparent that many prolifer-
ating normal cells express telomerase activity at a lower level.
Among these are human activated lymphocytes and several types
ofepithelium (Tayloret al, 1996; Yasumoto et al, 1996: Engelhardt
et al. 1997). This study performed on the cervix demonstrated
similarfindings. A low level oftelomerase activity was detectable
in nornal cervical tissues andbenign lesions and may be necessary
for theirphysiological proliferation. On the other hand, thepattern
of telomerase expression in SILs and carcinoma cases indicates
that telomerase is involved during cancer development and acti-
vated during the late stage ofmultistep carcinogenesis.
In order to identify whether and how HPV is associated with
telomerase activity, several cervical samples were tested by means
ofTRAP assay and HPV DNA detection using LI and E6 primers.
Both techniques are very specific and sensitive methods. The TRAP
assay could detect telomerase activity from as few as ten immortal
cells. The newprimer set, the internal control and two-step reactions
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Figure 3 Telomerase activity in epithelium of cervical tissues (+ and -. with and without RNAase pretreatment respectively). ITAS. internal telomerase assay
standard. Extracts of Epstein-Barr virus transformed human lymphocyte cell lines were used as positive control. Serial dilution of 1W. 102 and ten cells
represented levels of actvity of the enzyme. CHAPS tysis buffer (B) was used as negative control. T represents tissue before collagenase treatment. E and C
represent epitellum and connective tissues after colLagenase treatment respectively. C58 was cervicitis and C54 was high-grade SILs
helped solve problems regarding false-positive and negative-results
due to primer dimers and PCR inhibitors respectively. In cases of
HPV detection. consensus and type-specific oligonucleotide probes
used in hybridization analysis of LI amplification products wvere
shown to detect as few as ten copies of HPV of many known and
more than 25 novel HPV types (Resnick et al 1990). The second
consensus primer set wasdesigned to amplify a240-bpregion ofthe
E6 gene and helped improve the analysis of low-qualitv DNA
(Resnick et al 1990). Thus, using, these two methods should be
appropriate to compare the telomerase activity between HPV-posi-
tive and -negative groups.
Our data showed that the presence of high-risk HPV %-as not
associated w-ith telomerase activation in benign cervical lesions.
Only 20% of HPV-positive benign cervical lesions. four cases of
high-risk and one case ofunknown type. expressed telomerase. On
the contrarv. 52% of the HPV-negative group showed enzvme
activit}. Although this data did not imply that HPV could not
activate telomerase in benign cervical lesions. HPV does not play
a crucial role and other mechanism(s) might be involved.
HPV 16
2
3
Figure 4 Dot-blot hybndization for HPV 16 probe. Lanes al-f1 were
positive controls using purified plasmids of HPV type 6. 11, 16, 18. 31 and 33
respectively. Lane gi was extracted DNA from HeLa cells. Lanes a2-g2 were
invasive carcinoma lesions. Lanes a3-d3 and e3-g3 were cervicitis and
normal cervix respectively
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One of the most crucial parts played by HPV in cervical
carcinogenesis is activation oftelomerase. It will be interesting to
explore whether HPV infection alone or additional genetic alter-
ations are required for telomerase activation during cervical
carcinogenesis. Several studies performed on the transforming
activity ofHPV have shown the capability ofhigh-risk HPV E6 to
transform cells to the immortalized state. One study on human
keratinocyte retrovirus-mediated transduction found that the E6
protein alone was sufficient for early telomerase activation
(Klingelhutz et al 1996; Stoppler et al 1997). However, another
study on human keratinocytes transfected with full-length, high-
risk HPV has shown additional genetic events to be required for
increased levels of telomerase expression (Steenbergen et al,
1996). Our data showed that 50%, 80% and 95% ofHPV-positive
SILs, MIC and squamous-cell cancerexpressed telomerase respec-
tively. This provided evidence that the transforming activity of
high-risk-type HPV did not encompass telomerase activation at the
initiation of cervical carcinogenesis, but might be triggered by
subsequent genetic aberrations at some later stage.
Previous studies demonstrated that telomerase activity was
detectable in cervical scrapings, suggesting that the TRAP assay is
a useful screening method for cervical lesions, especially when
combined with a Pap smear test (Kyo et al 1997). However, our
results demonstrated that more than 40% of benign lesions and
nornal cervical tissues were positive in the TRAP assay. regard-
less of their HPV status. This may limit the usefulness of this
application. Nevertheless, as a very high frequency oftelomerase
expression was observed in the early invasive lesions, this enzyme
activity may constitute a biomarker regarding malignant transfor-
mation or invasiveness. It may be worth pursuing the clinical
usefulness ofthis molecular marker in the future.
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